Chase Doyle
- Director of Operations, AUDITLab Pro
Los Angeles
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chase Doyle
Disease-Free Survival With Gemcitabine Intravesical System in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Findings from the SunRISe-1 trial showed that TAR-200 appears to be safe and active, signaling a step forward for papillary-only disease (Ta or T1) in...
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non-Muscle-Invasive Bladder Cancer
Intravesical treatment with the investigational immunotherapy cretostimogene grenadenorepvec (CG0070) demonstrated “strong” high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Topline results from Cohort P of the multinational, single-arm phase III BOND-003 study showed a 95.7%...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease-Free Survival in Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine therapy, according to data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).1 Results from the global, randomized lidERA Breast Cancer trial position giredestrant as a potential new...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathological complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or declined cisplatin-based chemotherapy.
Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Findings from the SunRISe-1 trial showed that TAR-200 appears to be safe and active, signaling a step forward for papillary-only disease (Ta or T1) in...
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to effectively guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Results of an exploratory subgroup analysis of the phase III IMvigor011 trial showed that adjuvant atezolizumab provided significant benefit to ctDNA-positive patients while sparing ctDNA-negative patients from potentially...
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non-Muscle-Invasive Bladder Cancer - The ASCO Post
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated strong high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Topline results from Cohort P of the multinational, single-arm phase III BOND-003 study showed a 95.7% 3-month, 84.6% 6-month, and 80.4% 9-month...
Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated a high overall complete response rate in patients with high-risk, bacillus Calmette-Guérin (BCG)-naive non–muscle-invasive bladder cancer with carcinoma in situ, according to early results from Cohort A of the phase II CORE-008 trial.
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression-Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-naive prostate cancer.
177Lu-PSMA-617 Plus Hormone Therapy Improves Radiographic Progression-Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; 177Lu-PSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-naive prostate cancer.
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2025.1 This targeted therapy binds to the fibroblast growth factor receptor 2b (FGFR2b) protein, and mFOLFOX is a...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following EGFR tyrosine kinase inhibitor therapy.
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.
Zidesamtinib Shows Activity in Pretreated and Tyrosine Kinase Inhibitor–Naive Patients With ROS1-Positive NSCLC
Zidesamtinib, an investigational oral, highly selective ROS1 tyrosine kinase inhibitor designed to overcome common resistance mechanisms and improve brain penetration, has demonstrated activity in both pretreated and tyrosine kinase inhibitor–naive patients with ROS1-positive non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1 Zidesamtinib has been granted Breakthrough...
Osimertinib Plus Chemotherapy Significantly Prolongs Overall Survival in EGFR-Mutated Advanced NSCLC
The combination of the EGFR-targeting tyrosine kinase inhibitor osimertinib with platinum-based chemotherapy significantly improved overall survival as a first-line treatment for patients with EGFR-mutated, advanced, non–small cell lung cancer (NSCLC) compared with osimertinib monotherapy, according to the final overall survival data presented by David Planchard, MD, PhD, thoracic oncologist and Head of the Thoracic Pathology Committee at Gustave Roussy, Villejuif, France, at the...
Adding Nivolumab to Adjuvant Chemoradiotherapy Reduces Risk of Recurrence in Patients With Head and Neck Cancer
Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are at high risk for recurrence, according to data presented at the 2025 ASCO Annual Meeting.1 At a median follow-up of 30.3 months, results from the phase III NIVOPOSTOP trial demonstrated a significant improvement in disease-free survival, from 52.5% in the control group to 63.1% among patients...
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results from the phase III inMIND trial demonstrated a significant reduction in the risk of disease progression, relapse, or death by 57% when tafasitamab was added to lenalidomide and rituximab, compared...
Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader (SERD) camizestrant, researchers reported during the Plenary Session at the 2025 ASCO Annual Meeting.1 The study was concurrently published in TheNew England Journal of Medicine.2 Based on these...
Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions
Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented during the 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting.1 Primary results from the phase II multicenter POWER trial showed that this preoperative window allowed patients to gauge...
Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds
Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to hydroxyurea, according to data from the phase III SURPASS-ET trial presented at the European Hematology Association (EHA) 2025 Congress (Abstract S102).
Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the European Hematology Association (EHA) 2025 Congress (Abstract S230).
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data presented at a press briefing ahead of the 2025 ASCO Annual Meeting.1 At a median follow-up of 15 months, median progression-free survival more than doubled from 2.1 months with atezolizumab alone to 5.4...
Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC
Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated, HER2-mutant non–small cell lung cancer (NSCLC), according to data presented by John V.
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented at the 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting.1 Analysis of the large NRG Oncology/NSABP B-35 trial found that differences in 10-year ipsilateral breast tumor recurrence...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior to conventional fractionation in patients with breast cancer who underwent breast reconstruction after mastectomy.
Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function.
Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer
Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 trial. Researchers have halted this large, randomized phase II/III trial after patients in the control arm reached an unprecedented 2-year progression-free survival rate of 98%, setting a new benchmark for treatment efficacy in early-stage, HPV-associated oropharyngeal cancer.
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 Preliminary results from the multicenter phase III SCIENCE trial conducted in China revealed that neoadjuvant chemoradiotherapy combined with sintilimab achieved a...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Primary results of the phase III inMIND trial demonstrated a median progression-free survival of 22.4 months with tafasitamab vs 13.9 months in the placebo arm,...
Closing the Door on Barrett’s: The Critical Role of Reflux Control in EET Outcomes
Originally published by our sister publication Gastroenterology & Endoscopy News By Chase Doyle and Sarah Tilyou DENVER—Despite two decades of progress in ablation techniques, the incidence of esophageal cancer has remained largely unchanged, prompting some experts to reevaluate their approach to management of Barrett’s esophagus. In a presentation at the 2024 annual meeting of the American Foregut Society.
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators shared cutting-edge results that promise to shape future treatment strategies.
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition.1 Initial results of the ECOG-ACRIN EA4151 trial showed that ASCT provided no significant benefit in overall survival or progression-free survival...
Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Additional follow-up data from the phase III EV-302 trial, which evaluated enfortumab vedotin plus pembrolizumab as a first-line...
Nivolumab Plus Cabozantinib Continues to Show Superior Long-Term Outcomes in Advanced Renal Cell Carcinoma
The PD-1 inhibitor nivolumab plus the tyrosine kinase inhibitor cabozantinib continues to demonstrate a significant survival advantage over sunitinib alone in patients with previously untreated advanced renal cell carcinoma, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 With a median follow-up of 67.6 months, final results from the phase III CheckMate 9ER trial showed a median overall survival of 46.5 months for patients randomly assigned to receive nivolumab...
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase III PCS4 trial, which randomly assigned 515 patients to receive either 18 or 36 months of androgen-deprivation therapy in combination with radiotherapy, demonstrated a 46% reduction in mortality...
Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium1 and published simultaneously in Nature Medicine.2 These findings were presented by lead investigator Scott Kopetz, MD, PhD, FACP, Deputy Chair for Translational Research and...
Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup
An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor nivolumab plus the CTLA-4 inhibitor ipilimumab vs single-agent nivolumab in patients with microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer.
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of particular interest at the conference.
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary disease.
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both front-line and relapsed or refractory disease.
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Findings from the phase III BOREAS study showed navtemadlin nearly tripled spleen volume reductions and doubled symptom score improvements compared with best available...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer, according to data presented by lead study author Rachel Elizabeth Rau, MD, Associate Professor of Pediatrics at Seattle Children’s Hospital and the University of Washington, at the 2024 American Society of...
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published simultaneously in The New England Journal of Medicine.2 Results from the phase III TOPGEAR trial demonstrated higher rates of pathologic complete response and tumor downstaging in the chemoradiation arm compared...
In Case You Missed It: Roundup From ESMO Congress 2024
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest.
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer.1 Results from the FURTHER trial (FURMO-002; ClinicalTrials.gov identifier NCT05364073), a global randomized study evaluating...
New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies
Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this challenging subset of lung cancer cases.
Durvalumab Plus Chemotherapy Improves Overall Survival in Localized Muscle-Invasive Bladder Cancer
The addition of the PD-L1 inhibitor durvalumab to standard neoadjuvant gemcitabine/cisplatin chemotherapy has demonstrated statistically significant and clinically meaningful improvements in survival compared with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024 and simultaneously published in The New England Journal of Medicine.1,2 ‘Major Step Forward’ The...
Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024
At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and artificial intelligence (AI)-driven pathology analysis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chase
Contact Chase, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack